Neurology
ERG has conducted more than 400 clinical trials in those suffering from Alzheimer’s disease.
16
sites with neurology expertise
1,600+
neurology studies
11%
Top enrollers in 11% of studies
As scientists continue unlocking the human genome, they discover new methods of diagnosing and treating neurological disease—and ERG is at the forefront of translating this basic research into clinical solutions by advancing neurological clinical research studies.
Demonstrated Expertise in Key Indications
- ALS
- Alzheimer’s Disease
- Autism
- Cognitive Impairment
- Dementia
- Epilepsy
- Essential Tremor
- Huntington’s Disease
- Lewy Body Dementia
- Migraine
- Movement Disorders
- Multiple Sclerosis
- Parkinson’s Disease
- Primary Degenerative Dementia
- Seizure Disorders
- Stuttering
- Tardive Dyskinesia
- Tourette’s Syndrome (adult and adolescent)
- Vascular Dementia
Studies from First-in-Man Through Phase III
ERG’s exceptional expertise and long-standing work in neurology spans every study type—including increasing numbers of studies investigating both large and small molecules given through a variety of delivery systems.
Industry-Leading Neurologic Expertise
At ERG sites, the principal investigators who helm neurology clinical trials include industry experts, advisors to large pharmaceutical companies, and small biotechs alike. They are joined by neuropsychiatric/neurocognitive raters, certified movement disorder clinicians and raters, licensed clinical psychologists, licensed compounding pharmacists, and a staff specifically trained to work with these populations.
ERG’s Experienced Neurology Team
Jim Aukstuolis, MD
Robert Billingsley, Jr., MD
Mark Brody, MD
Otto Dueno, MD
Arthur Flippin, MD
Steven Folkerth, MD
Ana Fuquay, MS, CCRC
Daniel Gruener, MD
George Konis, MD
Daniel Lawler, MD
Stephen Thein, PhD
Shari DeSilva, MD
Affiliate Neurology Team
Paul Miller, MD
Concetta Forchetti, MD
Sanjiv Sharma, MD
Michelle Papka, PhD
Nick Vatakis, MD
Specialized Resources for Neurologic Research Studies
ERG’s dedicated standalone clinical research units offer access to a full spectrum of neuroimaging and psychometric testing for cognitive disorder, as well as APOE genetic testing, onsite cerebrospinal fluid (CSF) sampling and serial CSF sampling capabilities in CLIA-Waived laboratories. We also are able to house both patients and caregivers for short- or long-term clinical research studies.
ERG helps boost compliance in memory loss and Alzheimer’s disease studies by locating sites in communities with a predominantly senior population, increasing convenience for study participants.
Targeted Patient Recruitment
ERG’s dedicated recruitment team starts with our robust network of referring neurologists, family practitioners, and psychiatrists/ psychologists, as well as community outreach—especially in snowbird locations with large elderly populations. We bolster those efforts by working closely with targeted affiliations, such as the Alzheimer’s Association, the Global Alzheimer’s Platform, the International Essential Tremor Foundation and The Michael J. Fox Foundation. All these recruitment sources simply extend our own robust database of over 215,000 patients, ensuring rapid enrollment for neurological clinical research trials.
Spotlight
Stephen Thein, PhD
- Conducted 600+ clinical studies
- Industry-leading researcher in the field of memory and Alzheimer’s disease
- Authored 20+ peer-reviewed journal articles and scientific abstracts
Mark Brody, MD Joins AD Advisory Board
Florida’s AD Research Grant Advisory Board help guide the state Surgeon General on appropriations by the Ed and Ethel Moore Alzheimer’s Disease Research Program.
APOE Genetic Testing
Three independent memory clinics investigate whether on-site rapid APOE testing helps boost recruitment of patients into Alzheimer’s disease clinical trials.